Discovery of New Innate Immune Pathways in Viral Recognition

病毒识别中新先天免疫途径的发现

基本信息

  • 批准号:
    8653231
  • 负责人:
  • 金额:
    $ 316.37万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-03-01 至 2019-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (as provided by applicant): A major conceptual advance in innate immunity is the discovery of Pathogen Recognition Receptors (PRR), which profoundly shape adaptive immunity to affect host response to pathogens. Major PRRs crucial for innate immunity against viral pathogens include toll-like receptors and RIG-I like receptors, while the role for NLR (nucleotide-binding leucine rich repeat containing, or NOD-like receptor) family in viral infection is just emerging. In this Program, we will focus on the revelation of novel nucleic acid sensing pathways relevant to multiple NIAID priority pathogens. The Program is comprised of three Projects, each led by an international leader in his/her field. The Program will be performed in a highly collaborative fashion with two Cores which will provide cutting edge proteomics and protein purification capabilities, headed by directors who have contributed seminal work in the field of PRRs. The overarching goals are: * To investigate the role of novel PRRs as receptors of viral nucleic acid which affect subsequent innate immune responses to NIAID high priority viral pathogens in human. * To apply cutting edge quantitative proteomic approaches for the identification of novel paradigm-shifting pathways of pathogen sensing. * To contrast and compare role of PRRs across diverse NIAID high priority human viruses. * To reveal cross-talk between multiple PRRs in host response to NIAID priority human viruses * To investigate intracellular trafficking of viral ligands to sites of recognition by PRRs. * To capitalize on unique biochemical capabilities that are technically challenging to quantify the ligand-binding functions of PRRs. * To maximize opportunities for validating experimental findings with primary human materials. These goals are highly response to the RFA-AI-12-048 and are in precise concordance with the stated purpose of the RFA that "emphasis of research proposed in response to this FOA should be in defining novel cellular and molecular immune mechanisms involved in immunity to virus infection". It is also responsive because the pathways explored are broadly relevant to multiple high priority pathogens and will be studied in the context of five high priority RNA and DNA viruses. Finally, the proposed work is responsive to the purpose of the RFA because it specifically expands our understanding of novel PRR interaction with viruses and the accompanied changes in signaling pathways by profiling proteomic modifications in human innate immune cells caused by NIAID priority viral pathogens.
描述(由申请人提供):先天免疫的一个重要概念进展是病原体识别受体(PRR)的发现,它深刻地塑造适应性免疫,影响宿主对病原体的反应。对病毒病原体的先天免疫至关重要的主要PRRs包括toll样受体和RIG-I样受体,而NLR(核苷酸结合富亮氨酸重复序列,或nod样受体)家族在病毒感染中的作用

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jenny P Ting其他文献

Jenny P Ting的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jenny P Ting', 18)}}的其他基金

Intracellular Innate Immune Receptors in Cancer Suppression and Immunotherapy
细胞内先天免疫受体在癌症抑制和免疫治疗中的作用
  • 批准号:
    10654660
  • 财政年份:
    2019
  • 资助金额:
    $ 316.37万
  • 项目类别:
Intracellular Innate Immune Receptors in Cancer Suppression and Immunotherapy
细胞内先天免疫受体在癌症抑制和免疫治疗中的作用
  • 批准号:
    10451800
  • 财政年份:
    2019
  • 资助金额:
    $ 316.37万
  • 项目类别:
Intracellular Innate Immune Receptors in Cancer Suppression and Immunotherapy
细胞内先天免疫受体在癌症抑制和免疫治疗中的作用
  • 批准号:
    10217045
  • 财政年份:
    2019
  • 资助金额:
    $ 316.37万
  • 项目类别:
Intracellular Innate Immune Receptors in Cancer Suppression and Immunotherapy
细胞内先天免疫受体在癌症抑制和免疫治疗中的作用
  • 批准号:
    10019472
  • 财政年份:
    2019
  • 资助金额:
    $ 316.37万
  • 项目类别:
Novel Nanoparticle Platform for the delivery of Vaccines and Adjuvants
用于输送疫苗和佐剂的新型纳米颗粒平台
  • 批准号:
    8642227
  • 财政年份:
    2014
  • 资助金额:
    $ 316.37万
  • 项目类别:
Novel Nanoparticle Platform for the delivery of Vaccines and Adjuvants
用于输送疫苗和佐剂的新型纳米颗粒平台
  • 批准号:
    9229872
  • 财政年份:
    2014
  • 资助金额:
    $ 316.37万
  • 项目类别:
Engineering Monodisperse Particulate Vaccines to Tailor Immunological Responses
设计单分散颗粒疫苗以定制免疫反应
  • 批准号:
    9337971
  • 财政年份:
    2014
  • 资助金额:
    $ 316.37万
  • 项目类别:
Novel Nanoparticle Platform for the delivery of Vaccines and Adjuvants
用于输送疫苗和佐剂的新型纳米颗粒平台
  • 批准号:
    9307701
  • 财政年份:
    2014
  • 资助金额:
    $ 316.37万
  • 项目类别:
Novel Nucleic Acid Sensing NLRs and Innate Immunity to Viruses
新型核酸传感 NLR 和病毒先天免疫
  • 批准号:
    9233910
  • 财政年份:
    2014
  • 资助金额:
    $ 316.37万
  • 项目类别:
NOD-like Receptors in Intestinal Inflammation
肠道炎症中的 NOD 样受体
  • 批准号:
    10447741
  • 财政年份:
    2013
  • 资助金额:
    $ 316.37万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 316.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 316.37万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 316.37万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 316.37万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 316.37万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 316.37万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 316.37万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 316.37万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 316.37万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 316.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了